**What is already known about the topic?**

-   Holistic breathlessness services for people with advanced disease and chronic breathlessness can improve psychological aspects of their breathlessness and health.

-   Outcomes within and between trials show inconsistencies, which may relate to patient characteristics.

**What this paper adds?**

-   Baseline mastery and distress due to breathlessness predict outcomes following holistic breathlessness services.

-   Diagnosis, lung function and health status do not influence outcomes following holistic breathlessness services.

**Implications for practice, theory or policy**

-   Patients should be considered as candidates for holistic breathlessness services regardless of their diagnosis, lung function and health status.

-   Where trials and clinical services face limited resources, prioritising patients with low levels of mastery and/or high levels of distress due to breathlessness appears appropriate.

Introduction {#section7-0269216319830299}
============

Holistic breathlessness services have been developed for people with advanced disease and chronic breathlessness (i.e. breathlessness that remains persistent despite optimal treatment of the underlying disease^[@bibr1-0269216319830299]^). These typically combine input from multiple-specialities (e.g. palliative care, respiratory care) and professions (e.g. medicine, nursing, physiotherapy) to offer comprehensive assessment of patient and carer needs, and tailored pharmacological and non-pharmacological breathlessness management.^[@bibr2-0269216319830299]^ In chronic respiratory disease, such services represent an evidence-based means for early integration of palliative care based on need rather than prognosis.^[@bibr3-0269216319830299]^

Overall, holistic breathlessness services lead to improvements in mastery (i.e. patients' feeling of control over their disease^[@bibr4-0269216319830299]^), distress due to breathlessness and psychological health.^[@bibr2-0269216319830299]^ However, treatment outcomes across and within trials is inconsistent,^[@bibr2-0269216319830299]^ and the extent to which patient characteristics influence this is unclear. Breathlessness itself is associated with poor physical and mental health,^[@bibr5-0269216319830299]^ which may influence how patients interact with services. Other factors including health status, exercise capacity, anxiety and depression may also influence outcomes, as they can for pulmonary rehabilitation.^[@bibr6-0269216319830299][@bibr7-0269216319830299][@bibr8-0269216319830299]--[@bibr9-0269216319830299]^ We aimed to identify patient predictors of outcomes from holistic breathlessness services, focusing on improved mastery and reduced distress due to breathlessness.

Methods {#section8-0269216319830299}
=======

Design {#section9-0269216319830299}
------

We conducted a secondary analysis of pooled individual patient data from three trials of holistic breathlessness services for patients with advanced malignant and non-malignant conditions, delivered over 2--6 weeks.^[@bibr10-0269216319830299][@bibr11-0269216319830299]--[@bibr12-0269216319830299]^ The original data were collected between 2008 and 2012. Our methods built on those in an analysis of patient predictors of response to opioids.^[@bibr13-0269216319830299]^

Analysis {#section10-0269216319830299}
--------

Our primary analysis considered improvements on the Chronic Respiratory Questionnaire (CRQ) mastery domain, defined as a 0.5 point increase in line with the minimum clinically important difference.^[@bibr14-0269216319830299]^ This outcome was measured in all trials and was the primary outcome in the Higginson et al.^[@bibr10-0269216319830299]^ trial. A secondary analysis considered improvements on Numerical Rating Scale (NRS) distress due to breathlessness (NRS distress), defined as a 1-point reduction.^[@bibr15-0269216319830299]^ This was the primary outcome in the two Farquhar et al.^[@bibr11-0269216319830299],[@bibr12-0269216319830299]^ trials but was not measured in the Higginson et al.^[@bibr10-0269216319830299]^ trial.

Candidate variables (and their reference group/possible score ranges) for the primary and secondary analysis were selected based on availability within the dataset. They included age, sex, diagnosis (reference: COPD), FEV~1~ % predicted and baseline scores for CRQ dyspnoea, fatigue, mastery and emotional domains (1--7), EuroQol-5D (EQ5D) Utility Index (--1 to 1) and Visual Analogue Scale (VAS; 0--100), Hospital Anxiety and Depression Scale (HADS) anxiety and depression scores (0--21), and NRS average breathlessness in the previous 24 h (NRS average; 0--10). Baseline NRS distress (0--10) was included only in the secondary analysis. For all variables, the timepoint immediately pre-intervention for each group was treated as 'baseline' (e.g. in the Higginson trial, fast-track participants' baseline was week 1, wait-list participants' baseline was week 6).

Variables significantly related to improvements by the minimum clinically important difference (*p* \< 0.05) in univariate logistic regression models were considered in separate multivariate analyses for CRQ mastery and NRS distress. We used backwards stepwise logistic regression modelling, with sequential removal of variables with the largest non-significant (*p* \> 0.05) *p* value in each model. Age, sex (reference: male) and trial (reference: Farquhar et al. 2016) were forced into both models to control for these clinically relevant variables. This secondary analysis of anonymised data did not require ethical approval (references for each contributing study: King's College Hospital 10/H0808/17; Cambridgeshire 2 NHS 08/H0308/157).

Results {#section11-0269216319830299}
=======

Participants {#section12-0269216319830299}
------------

The pooled dataset comprised 259 participants (118 female) with a mean (SD) age of 69.2 (10.6) years ([Table 1](#table1-0269216319830299){ref-type="table"}). The most common primary diagnosis was COPD (49.8%), followed by cancer (34.7%) and interstitial lung disease (10.4%).

###### 

Sample characteristics.

![](10.1177_0269216319830299-table1)

  Variable                                                                                 Mean (SD)/*n* (%)                               
  ---------------------------------------------------------------------------------------- ------------------- ------------- ------------- --------------
  Age                                                                                      67.0 (9.9)          68.7 (11.5)   72.2 (10.0)   69.2 (10.6)
  Female sex                                                                               44 (41.9)           40 (60.6)     34 (39.1%)    118 (45.6%)
  Diagnosis                                                                                                                                
   COPD                                                                                    55 (52.4%)          --            74 (85.1%)    129 (49.8%)
   ILD                                                                                     19 (18.1%)          --            8 (9.2%)      27 (10.4%)
   Cancer                                                                                  22 (21.0%)          67 (100%)     1 (1.1%)      90 (34.7%)
   Other                                                                                   9 (8.6%)            --            4 (4.6%)      13 (5%)
  FEV~1~ % predicted                                                                       46.1 (24.2)         --            46.2 (21.4)   46.1 (22.9)
  NRS                                                                                                                                      
   Breathlessness (ave. 24 h)^[a](#table-fn2-0269216319830299){ref-type="table-fn"}^       5.99 (2.07)         3.93 (1.96)   4.38 (1.86)   4.89 (2.16)
   Distress due to breathlessness^[a](#table-fn2-0269216319830299){ref-type="table-fn"}^   --                  4.85 (2.90)   5.21 (2.74)   5.06 (2.80)
  HADS                                                                                                                                     
   Anxiety^[a](#table-fn2-0269216319830299){ref-type="table-fn"}^                          9.39 (2.90)         7.36 (3.82)   8.20 (4.01)   8.44 (3.64)
   Depression^[a](#table-fn2-0269216319830299){ref-type="table-fn"}^                       10.36 (2.93)        6.44 (2.79)   7.23 (3.55)   8.24 (3.56)
  EQ5D                                                                                                                                     
   VAS                                                                                     53.3 (17.8)         57.8 (18.5)   54.4 (18.8)   54.8 (18.4)
   Utility Index                                                                           0.39 (0.32)         0.59 (0.24)   0.50 (0.28)   0.48 (0.29)
  CRQ                                                                                                                                      
   Dyspnoea                                                                                2.25 (0.81)         3.61 (1.07)   3.25 (0.96)   2.95 (1.09)
   Fatigue                                                                                 2.84 (1.38)         3.30 (1.22)   3.10 (1.08)   3.05 (14.25)
   Emotional function                                                                      3.72 (1.31)         4.44 (1.06)   4.09 (1.08)   4.03 (1.20)
   Mastery                                                                                 3.54 (1.40)         4.64 (1.17)   4.04 (1.24)   3.99 (1.36)
  Improvements by the MCID                                                                                                                 
   Mastery                                                                                 36 (51.4%)          17 (34.0%)    44 (59.5%)    97 (50%)
   NRS distress                                                                            --                  36 (69.2%)    45 (58.4%)    81 (62.8%)

COPD: chronic obstructive pulmonary disease; ILD: interstitial lung disease; NRS: Numerical Rating Scale; HADS: Hospital Anxiety and Depression Scale; EQ5D: EuroQol-5D; CRQ: Chronic Respiratory Questionnaire; MCID: minimum clinically important difference.

Lower scores desirable.

CRQ mastery {#section13-0269216319830299}
-----------

Of the participants for whom CRQ mastery outcomes could be calculated, 97/194 (50%) were classified as improving by the minimum clinically important difference. In univariate analyses, baseline variables significantly associated with improvements in CRQ mastery were baseline CRQ mastery (*p* \< 0.001), dyspnoea (*p* = 0.008) and fatigue (*p* = 0.009); EQ5D Utility Index (*p* = 0.007) and VAS (*p* = 0.014); and NRS average (*p* = 0.039). Controlling for age, sex and trial in the multivariate modelling, baseline CRQ mastery remained the only significant predictor of outcomes. Participants with higher CRQ mastery scores at baseline (i.e. better mastery) were less likely to improve by the minimum clinically important difference, with a 43% decrease in odds for a 1-point increase at baseline (odds ratio (OR) 0.57, 95% confidence interval (CI) 0.43--0.74; *p* \< 0.001; [Table 2](#table2-0269216319830299){ref-type="table"}).

###### 

Predictors of outcomes in multivariate logistic regression.

![](10.1177_0269216319830299-table2)

  Variable                                                                                                   Odds Ratio   (95% Confidence Interval)   *p*
  ---------------------------------------------------------------------------------------------------------- ------------ --------------------------- ---------------------------------------------------------------
  CRQ mastery improvements by the MCID (*n* = 188)^[b](#table-fn5-0269216319830299){ref-type="table-fn"}^                                             
   Original study: Farquhar 2014^[a](#table-fn4-0269216319830299){ref-type="table-fn"}^                      0.43         (0.19--1.00)                0.05
   Original study: Higginson^[a](#table-fn4-0269216319830299){ref-type="table-fn"}^                          0.62         (0.29--1.31)                0.21
   Age                                                                                                       1.02         (0.99--1.05)                0.13
   Female sex                                                                                                1.68         (0.87--3.24)                0.12
   Baseline CRQ mastery                                                                                      0.57         (0.43--0.74)                \<0.001[\*](#table-fn7-0269216319830299){ref-type="table-fn"}
  NRS distress improvements by the MCID (*n* = 128)^[c](#table-fn6-0269216319830299){ref-type="table-fn"}^                                            
   Original study: Farquhar 2014^[a](#table-fn4-0269216319830299){ref-type="table-fn"}^                      2.40         (0.95--6.09)                0.06
   Age                                                                                                       1.03         (0.99--1.07)                0.18
   Female sex                                                                                                2.31         (0.94--5.72)                0.07
   Baseline NRS distress                                                                                     1.64         (1.35--2.03)                \<0.001[\*](#table-fn7-0269216319830299){ref-type="table-fn"}

CRQ: Chronic Respiratory Questionnaire; NRS: Numerical Rating Scale; MCID: minimum clinically important difference.

Reference: Farquhar 2016.

CRQ mastery model: X2 (5, *n* = 188) = 31.309, *p* \< 0.001.; AUC = 0.729.

NRS distress model: X2 (4, *n* = 128) = 39.258, *p* \< 0.001.; AUC = 0.820.

Significant at *p* \< 0.05.

NRS distress due to breathlessness {#section14-0269216319830299}
----------------------------------

Of the participants for whom NRS distress outcomes could be calculated, 81/129 (62.8%) were classified as improving by the minimum clinically important difference. The only variable significantly associated with NRS distress outcomes in the univariate analysis was baseline NRS distress (*p* \< 0.001). This remained significant in the multivariate model controlling for age, sex and trial. For every 1-point increase in baseline NRS distress the odds of improving by the minimum clinically important difference increased by 64% (OR 1.64; 95% CI 1.35--2.03; *p* \< 0.001; [Table 2](#table2-0269216319830299){ref-type="table"}).

Discussion {#section15-0269216319830299}
==========

Our findings reveal that baseline CRQ mastery and NRS distress are strong predictors of outcomes from holistic breathlessness services; other patient characteristics we considered, including diagnosis, are not associated with treatment outcome. Clinical services and future trials may therefore consider focusing efforts on patients with poor psychological health relating to their breathlessness, based on screening questions. To illustrate this, in a post hoc analysis of outcomes according to unadjusted baseline CRQ mastery, 75% of patients with a score of ⩽2 improved by the minimum clinically important difference, while just 28% of those with a score of ⩾5 did so. For NRS distress, 89% of patients with a 'severe' score (⩾7) improved by the minimum clinically important difference compared with 39% of those with a 'mild' baseline score (⩽3). With high levels of health service use in breathless patients and limited resources, factors to inform prioritised access to holistic breathlessness services based on likelihood of benefit may be useful.

It is notable that outcomes were not influenced by breathlessness severity, patient diagnosis, lung function, overall health status, anxiety or depression. In some instances, this finding may relate to baseline scores within our sample. For example, baseline scores indicated only mild anxiety and depression;^[@bibr16-0269216319830299]^ higher levels of psychological distress were therefore not considered within our analyses. However, this finding could also be a product of the tailored nature of these services, whereby individual clinical and demographic characteristics should be addressed.

This work has strengths and limitations. We combined individual patient-level data from three high-quality randomised controlled trials, resulting in a more powerful analysis than would be possible with any single trial. This approach meant our analyses were limited to variables common across the datasets. Potentially important patient factors (e.g. multi-morbidity, functional status) were not tested as they were not measured across all three trials, and fewer cases were available for our secondary analysis around distress. It is also important to acknowledge that there is no consensus on the optimal outcomes of holistic breathlessness services. While we have focused on mastery and distress due to breathlessness, another trial comparing one versus three sessions of a breathlessness service focused on worst breathlessness over the previous 24 h as a primary outcome. Future work may benefit from establishing a core set of clinically relevant patient characteristics and outcomes from breathlessness services, and consistently including these when assessing interventions. Our findings may reflect regression to the mean,^[@bibr17-0269216319830299]^ however, the magnitude of effects observed and consistent benefit across the controlled trials^[@bibr2-0269216319830299]^ suggest that this is not the only contributing factor. Finally, these data are limited to holistic breathlessness services trialled in the United Kingdom and may not transfer to international services.

Conclusion {#section16-0269216319830299}
==========

Outcomes of holistic breathlessness services in terms of improved mastery and reduced distress due to breathlessness are influenced by baseline scores for these variables, but not breathlessness severity, patient diagnosis, lung function, overall health status, or mild anxiety or depression. In future trials, and where clinical services face limited resources, selecting or prioritising patients with low levels of mastery or high levels of distress appears appropriate.
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